NCT01489345

Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

A Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Ono Pharma USA Inc · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to evaluate the safety and tolerability of ONO-2952 across ascending multiple doses in healthy adult male and female subjects. The secondary objective is to characterize the pharmacokinetic (PK) profile of ONO-2952.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	ONO-2952	30 mg to 100 mg QD at a multiple dose, and 21 days duration
DRUG	ONO-2952 Matching Placebo	30 mg to 100 mg QD at a multiple dose, and 21 days duration

Timeline

• Start date: 2011-12-01
• Primary completion: 2012-04-01
• First posted: 2011-12-09
• Last updated: 2012-08-01

Locations

1 site across 1 country: United States